

Special Issue

Angiogenesis and Related Disorders

Message from the Guest Editor

Angiogenesis is a complex biological process that involves the formation of new blood vessels from existing ones, which is crucial for normal development and wound healing. Pathological angiogenesis, however, contributes to many diseases, particularly cardiovascular diseases (such as atherosclerosis, stroke, pulmonary hypertension, and cardiac hypertrophy), cancer, diabetic retinopathy, and diabetic delayed wound healing. Understanding the role of angiogenesis in these disorders is essential for developing targeted therapies and improving patient outcomes.

- Therapeutic Target Identification: Identifying and understanding the molecular mechanisms that regulate angiogenesis in related disorders.
- Biomarker Discovery: Identifying biomarkers that can be used to diagnose, prognose, and monitor angiogenesis and related disorders.
- Drug Development and Preclinical Studies: Development and testing of novel or classical/clinical drugs and therapies targeting angiogenesis in related disorders.
- Clinical Implementation: Conducting clinical trials, optimizing treatment protocols, and developing guidelines for the management of angiogenesis and related disorders.

Guest Editor

Dr. Jian Li

Center for Molecular and Translational Medicine, Georgia State University, 157 Decatur Street, SE, Atlanta, GA 30303, USA

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/199162

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).